A short summary describing a next-generation BTK inhibitor with sustained and potent activity at disease sites and low off-target kinase inhibition.

Jacob D. Soumerai

Poster presented at ASH 2022 describing the potential for combining BCL2i and BTKi in patients with non-Hodgkin’s lymphoma (NHL), including separate cohorts for mantle cell lymphoma (MCL) and Waldenström’s macroglobulinemia (WM).


Factsheet describing the treatment of Waldenström’s macroglobulinemia (WM) by inhibiting BTK.

Chat with BeiGene